- Home
- ETV vs GLPG Comparison
ETV vs GLPG Comparison
Compare ETV & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
ETV
Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | ETV | GLPG |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 452 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | ETV | GLPG |
|---|---|---|
| Price | $14.75 | $27.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $36.50 |
| AVG Volume (30 Days) | ★ 164.3K | 129.6K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.10 | $25.97 |
| 52 Week High | $14.83 | $37.78 |
Technical Indicators
Market Signals| Indicator | ETV | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 61.87 | 36.53 |
| Support Level | $14.30 | N/A |
| Resistance Level | $14.82 | $34.04 |
| Average True Range (ATR) | 0.15 | 0.56 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 81.39 | 25.33 |
Price Performance
Historical ComparisonAbout ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.